Versão HTML básica
333
Scientific Comments
Rev Bras Hematol Hemoter. 2012;34(5):323-33
xxx
MJ, Perkins SL, Patte C; FAB LMB96 International Study Committee.
Excellent survival following two courses of COPAD chemotherapy in
children and adolescents with resected localized B-cell non-Hodgkin’s
lymphoma: results of the FAB/LMB 96 international study. Br J
Haematol. 2008;141(6):840-7.
3. ReiterA, Schrappe M, TiemannM, LudwigWD, Yakisan E, Zimmermann
M, et al. Improved treatment results in childhood B-cell neoplasms with
tailored intensification of therapy: A report of the Berlin-Frankfurt-
Münster Group Trial NHL-BFM 90. Blood. 1999;94(10):3294-306.
4. Cairo MS, Gerrard M, Sposto R, Auperin A, Pinkerton CR, Michon J,
Weston C, Perkins SL, Raphael M, McCarthy K, Patte C; FAB LMB96
International Study Committee. Results of a randomized international
study of high-risk central nervous system B non-Hodgkin lymphoma
and B acute lymphoblastic leukemia in children and adolescents. Blood.
2007;109(7):2736-43.
5. Magrath I. Towards curative therapy in Burkitt lymphoma: the role of
early African studies in demonstrating the value of combination therapy
and CNS prophylaxis. Adv Hematol. 2012;2012:130680.
6. KC Cunha, MC Oliveira, AC Gomes, LP de Castro, MB Viana. Clinical
course and prognostic factors of children with Burkitt’s lymphoma in a
developing country: the experience of a single centre in Brazil. Rev Bras
Hematol Hemoter. 2012;34(5):361-6.
7. Woessmann W, Seidemann K, Mann G, Zimmermann M, Burkhardt B,
Oschlies I, LudwigWD, Klingebiel T, Graf N, Gruhn B, Juergens H, Niggli
F, Parwaresch R, Gadner H, Riehm H, Schrappe M, Reiter A; BFM Group.
The impact of the methotrexate administration schedule and dose in the
treatment of children and adolescents with B-cell neoplasms: a report of
the BFM Group Study NHL-BFM95. Blood. 2005;105(3):948-58.
8. Cairo MS, Krailo MD, Morse M, Hutchinson RJ, Harris RE, Kjeldsberg
CR, et al. Long-termfollow-up of short intensivemultiagent chemotherapy
without high-dose methotrexate (‘Orange’) in children with advanced
non-lymphoblastic non-Hodgkin’s lymphoma: a children’s cancer group
report. Leukemia. 2002;16(4):594-600.
9. Miles RR, Arnold S, Cairo MS. Risk factors and treatment of
childhood and adolescent Burkitt lymphoma/leukaemia. Br J Haematol.
2012;156(6):730-43.
10. Cairo MS, Coiffier B, Reiter A, Younes A; TLS Expert Panel.
Recommendations for the evaluation of risk and prophylaxis of tumour
lysis syndrome (TLS) in adults and children with malignant diseases: an
expert TLS panel consensus. Br J Haematol. 2010;149(4):578-86.
11. Meinhardt A, Burkhardt B, Zimmermann M, Borkhardt A, Kontny U,
Klingebiel T, Berthold F, Janka-Schaub G, Klein C, Kabickova E, Klapper
W, Attarbaschi A, Schrappe M, Reiter A; Berlin-Frankfurt-Münster group.
Phase II window study on rituximab in newly diagnosed pediatric mature
B-cell non-Hodgkin’s lymphoma and Burkitt leukemia. J Clin Oncol.
2010(19):3115-21. Comment in: J Clin Oncol. 2010;28(19):3104-6.